Karyopharm Therapeutics I...

4.08
0.22 (5.70%)
At close: Apr 07, 2025, 3:59 PM
4.21
3.19%
Pre-market: Apr 08, 2025, 07:44 AM EDT

Karyopharm Therapeutics Statistics

Share Statistics

Karyopharm Therapeutics has 8.42M shares outstanding. The number of shares has increased by 0.8% in one year.

Shares Outstanding 8.42M
Shares Change (YoY) 0.8%
Shares Change (QoQ) -0.46%
Owned by Institutions (%) 48.72%
Shares Floating 7.85M
Failed to Deliver (FTD) Shares 472
FTD / Avg. Volume 0.41%

Short Selling Information

The latest short interest is 19.8M, so 15.69% of the outstanding shares have been sold short.

Short Interest 19.8M
Short % of Shares Out 15.69%
Short % of Float 16.98%
Short Ratio (days to cover) 17.52

Valuation Ratios

The PE ratio is -16.17 and the forward PE ratio is -0.89. Karyopharm Therapeutics's PEG ratio is 0.33.

PE Ratio -16.17
Forward PE -0.89
PS Ratio 8.51
Forward PS 0.1
PB Ratio -6.64
P/FCF Ratio -9.68
PEG Ratio 0.33
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Karyopharm Therapeutics.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 1.7, with a Debt / Equity ratio of -0.54.

Current Ratio 1.7
Quick Ratio 1.64
Debt / Equity -0.54
Debt / EBITDA -2.59
Debt / FCF -0.78
Interest Coverage -3.19

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $520.56K
Profits Per Employee $-273.91K
Employee Count 279
Asset Turnover 0.88
Inventory Turnover 1.27

Taxes

Income Tax 57K
Effective Tax Rate -0.07%

Stock Price Statistics

The stock price has increased by -79.85% in the last 52 weeks. The beta is 0.59, so Karyopharm Therapeutics's price volatility has been higher than the market average.

Beta 0.59
52-Week Price Change -79.85%
50-Day Moving Average 7.43
200-Day Moving Average 11.02
Relative Strength Index (RSI) 32.05
Average Volume (20 Days) 114.95K

Income Statement

In the last 12 months, Karyopharm Therapeutics had revenue of 145.24M and earned -76.42M in profits. Earnings per share was -0.63.

Revenue 145.24M
Gross Profit 139.23M
Operating Income -119.44M
Net Income -76.42M
EBITDA -38.6M
EBIT -38.94M
Earnings Per Share (EPS) -0.63
Full Income Statement

Balance Sheet

The company has 62.48M in cash and 99.92M in debt, giving a net cash position of -37.45M.

Cash & Cash Equivalents 62.48M
Total Debt 99.92M
Net Cash -37.45M
Retained Earnings -1.56B
Total Assets 164.42M
Working Capital 64.23M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -127.49M and capital expenditures -142K, giving a free cash flow of -127.63M.

Operating Cash Flow -127.49M
Capital Expenditures -142K
Free Cash Flow -127.63M
FCF Per Share -1.05
Full Cash Flow Statement

Margins

Gross margin is 95.86%, with operating and profit margins of -82.24% and -52.62%.

Gross Margin 95.86%
Operating Margin -82.24%
Pretax Margin -52.58%
Profit Margin -52.62%
EBITDA Margin -26.58%
EBIT Margin -82.24%
FCF Margin -87.88%

Dividends & Yields

KPTI does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for KPTI is $54, which is 1223.5% higher than the current price. The consensus rating is "Buy".

Price Target $54
Price Target Difference 1223.5%
Analyst Consensus Buy
Analyst Count 4
Stock Forecasts

Stock Splits

The last stock split was on Feb 26, 2025. It was a backward split with a ratio of 1:15.

Last Split Date Feb 26, 2025
Split Type backward
Split Ratio 1:15

Scores

Altman Z-Score -12.69
Piotroski F-Score 3